Impacto Públicocivic observatory
Portuguêspt-PTEnglishcurrent languageEspañoles-ES

PUBLIC CONTRACT · 2026

2026/0503 - Convite à apresentação de proposta por ajuste direto para aquisição de A53293 - AMIVANTAMAB [50 MG/ML; 7 ML; SOL INJ; FRS], B466 - BOSENTANO [32 MG; COMP DISP], B925 - BEDAQUILINA [100 MG; CÁP/COMP]

Contract value
€2,352.72
Signed on
19 August 2026
Procedure
Direct award, general (Ajuste Direto Regime Geral)

This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.

Record 15735733

PUBLISHED DESCRIPTION

2026/0503 - Convite à apresentação de proposta por ajuste direto para aquisição de A53293 - AMIVANTAMAB [50 MG/ML; 7 ML; SOL INJ; FRS], B466 - BOSENTANO [32 MG; COMP DISP], B925 - BEDAQUILINA [100 MG;

Parties involved

Place of performance
Portugal, Viseu, Viseu
NUTS region
PT194 - Viseu Dão Lafões

WHO BID

Awardee and competitors

Companies that IMPIC lists as the awardee and as competitors in this procedure.

Awardee
JANSSEN CILAG FARMACEUTICA, LDA. · Tax ID 500189412

Values and timeline

Contract price
€2,352.72
Procedure base price
€372,292.80
Total effective price
Not reported on Portal BASE
Publication date
7 October 2026
Award date
19 August 2026
Signing date
19 August 2026
Performance period
151 days

The contract price is the value agreed in the contract, not the amount paid.

Procedure and framework

Contract type
Aquisição de bens móveis
Award criterion
Monofator
CPV code
33600000-6 - Produtos farmacêuticos
Legal basis
Artigo 24.º, n.º 1, alínea e), subalínea ii) do Código dos Contratos Públicos
Regime
Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
Framework agreement
Not stated
Centralised procedure
Yes
Environmental criterion
No
Notice
Not stated
Procedure identifier
11502919

Compare with other contracts

Search the same body, supplier, place or type of service to understand the context of the published index.

← Back to contracts